Published in Thorax on January 01, 1999
Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax (2003) 3.90
Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med (2006) 3.16
Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest (2015) 2.32
Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med (2006) 1.88
Exacerbation rate, health status and mortality in COPD--a review of potential interventions. Int J Chron Obstruct Pulmon Dis (2009) 1.85
Stable chronic obstructive pulmonary disease. BMJ (1999) 1.50
Association between lung function and exacerbation frequency in patients with COPD. Int J Chron Obstruct Pulmon Dis (2010) 1.35
Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax (2002) 1.27
Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications. Clin Ther (2008) 0.99
Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality. Int J Chron Obstruct Pulmon Dis (2007) 0.95
The challenge of providing better care for patients with chronic obstructive pulmonary disease: the poor relation of airways obstruction? Thorax (2000) 0.94
Herbal Formula, PM014, Attenuates Lung Inflammation in a Murine Model of Chronic Obstructive Pulmonary Disease. Evid Based Complement Alternat Med (2012) 0.92
An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease. Br J Clin Pharmacol (2006) 0.89
Clinical pharmacology = disease progression + drug action. Br J Clin Pharmacol (2015) 0.86
Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax (2002) 0.86
Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective. Br J Clin Pharmacol (2014) 0.84
Management of an acute exacerbation of copd: are we ignoring the evidence? Thorax (2002) 0.83
Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004. Thorax (2005) 0.83
Risk of adverse gastrointestinal events from inhaled corticosteroids. Pharmacotherapy (2008) 0.77
Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawal. NPJ Prim Care Respir Med (2016) 0.75
Inhaled steroids for COPD? Thorax (2001) 0.75
Inhaled corticosteroids in COPD. Thorax (1999) 0.75
Re-assessing the evidence about inhaled corticosteroids in chronic obstructive pulmonary disease. Thorax (1999) 0.75
Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl (1993) 20.55
Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA (1994) 10.46
Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J (1995) 7.03
A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. N Engl J Med (1992) 3.13
Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4-year prospective study. Ann Intern Med (1993) 2.77
Inhaled corticosteroids: benefits and risks. Thorax (1992) 2.17
Effects of long-term treatment with corticosteroids in COPD. Chest (1996) 1.94
Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol (1993) 1.91
Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction? Eur Respir J (1988) 1.56
Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group. Eur Respir J (1993) 1.32
Do patients with COPD benefit from treatment with inhaled corticosteroids? Eur Respir J (1996) 1.23
Severe chronic airflow obstruction: can corticosteroids slow down progression? Eur J Respir Dis (1985) 1.10
Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1995) 1.06
Failure of inhaled corticosteroids to modify bronchoconstrictor or bronchodilator responsiveness in middle-aged smokers with mild airflow obstruction. Chest (1992) 1.02
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35
Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med (1997) 8.48
Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J (1995) 7.03
Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med (1999) 4.65
Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma. Thorax (1999) 4.11
Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. BMJ (1991) 3.98
Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med (2000) 3.89
Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J (2005) 3.66
Air pollution and development of asthma, allergy and infections in a birth cohort. Eur Respir J (2007) 3.42
A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. N Engl J Med (1992) 3.13
Comorbidity of chronic diseases in general practice. J Clin Epidemiol (1993) 3.02
The specialist of the discipline of general practice. Semantics and politics mustn't impede the progress of general practice. BMJ (2000) 2.98
Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. N Engl J Med (2016) 2.89
Acute effects of cigarette smoke on inflammation and oxidative stress: a review. Thorax (2004) 2.85
Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4-year prospective study. Ann Intern Med (1993) 2.77
Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax (2005) 2.69
Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet (2001) 2.68
Enoxacin raises plasma theophylline concentrations. Lancet (1984) 2.46
Asthma at 8 years of age in children born by caesarean section. Thorax (2008) 2.45
The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol (1986) 2.43
Evaluation of the effectiveness of four different inhalers in patients with chronic obstructive pulmonary disease. Thorax (1995) 2.37
PC(20) adenosine 5'-monophosphate is more closely associated with airway inflammation in asthma than PC(20) methacholine. Am J Respir Crit Care Med (2001) 2.36
Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. BMJ (2002) 2.35
Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev (2005) 2.32
Independent influence of reversibility of air-flow obstruction and nonspecific hyperreactivity on the long-term course of lung function in chronic air-flow obstruction. Am Rev Respir Dis (1986) 2.29
Residual sleepiness in obstructive sleep apnoea: phenotype and related symptoms. Eur Respir J (2011) 2.28
Sex differences in cardiovascular disease: are women with low socioeconomic status at high risk? Br J Gen Pract (1999) 2.26
Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J (2008) 2.23
Severe exacerbations predict excess lung function decline in asthma. Eur Respir J (2007) 2.18
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
The clustering of respiratory diseases in early childhood. Fam Med (1994) 2.15
Are asymptomatic airway hyperresponsiveness and allergy risk factors for asthma? A longitudinal study. Eur Respir J (2008) 2.09
Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med (2001) 2.08
Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology (2000) 2.08
Inhaled corticosteroids in COPD: a case in favour. Eur Respir J (2009) 2.06
The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J (2004) 2.05
Decline of FEV1 by age and smoking status: facts, figures, and fallacies. Thorax (1997) 2.04
[Providing regular relief; considerations for palliative care in the Netherlands]. Ned Tijdschr Geneeskd (2001) 2.02
Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax (2000) 2.02
A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting beta(2)-agonists in allergic asthmatic patients. Chest (2001) 2.00
Association of a promoter polymorphism of the CD14 gene and atopy. Am J Respir Crit Care Med (2001) 1.99
Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group. Thorax (1992) 1.98
Interventions to improve the delivery of preventive services in primary care. Am J Public Health (1999) 1.96
Occlusion pressure as a measure of respiratory center output in conscious man. Respir Physiol (1975) 1.96
Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med (1999) 1.96
[The treatment of asthma: indications for a change in approach]. Ned Tijdschr Geneeskd (2006) 1.95
Effects of long-term treatment with corticosteroids in COPD. Chest (1996) 1.94
Quality of life in patients with chronic obstructive pulmonary disease improves after rehabilitation at home. Eur Respir J (1994) 1.91
Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project. Eur Urol (2002) 1.91
Childhood factors associated with asthma remission after 30 year follow up. Thorax (2004) 1.90
Anti-inflammatory effects of inhaled carbon monoxide in patients with COPD: a pilot study. Eur Respir J (2007) 1.90
Use of out of hours services: a comparison between two organisations. Emerg Med J (2003) 1.89
[Recent changes in the prevalence of asthma in children]. Ned Tijdschr Geneeskd (2006) 1.89
Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother (2001) 1.87
Parkinson's disease and sleepiness: an integral part of PD. Neurology (2002) 1.85
Prevalence of asthma and COPD in general practice in 1992: has it changed since 1977? Br J Gen Pract (1996) 1.85
Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy (2004) 1.84
Reliability and validity of the chronic respiratory questionnaire (CRQ). Thorax (1994) 1.84
Self-management of asthma in general practice, asthma control and quality of life: a randomised controlled trial. Thorax (2003) 1.84
Role of social support in lifestyle-focused weight management interventions. Eur J Clin Nutr (2005) 1.82
Evidence for a locus regulating total serum IgE levels mapping to chromosome 5. Genomics (1994) 1.81
Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol (1990) 1.80
Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet (2000) 1.78
Active detection of chronic obstructive pulmonary disease and asthma in the general population. Results and economic consequences of the DIMCA program. Am J Respir Crit Care Med (1998) 1.77
Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide. J Rheumatol (1993) 1.71
Spirometry in general practice: the performance of practice assistants scored by lung function technicians. Br J Gen Pract (1997) 1.71
Validity of spirometric testing in a general practice population of patients with chronic obstructive pulmonary disease (COPD). Thorax (2003) 1.70
Biomarker reproducibility in exhaled breath condensate collected with different condensers. Eur Respir J (2008) 1.70
Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma. Allergy (2010) 1.70
Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1996) 1.70
A comparison of six different ways of expressing the bronchodilating response in asthma and COPD; reproducibility and dependence of prebronchodilator FEV1. Eur Respir J (1992) 1.69
Can small group education and peer review improve care for patients with asthma/chronic obstructive pulmonary disease? Qual Health Care (1999) 1.66
Effects of physical activity in mild to moderate COPD: a systematic review. Br J Gen Pract (2002) 1.66
Identification and association of polymorphisms in the interleukin-13 gene with asthma and atopy in a Dutch population. Am J Respir Cell Mol Biol (2001) 1.65
Influence of the parasympathetic and sympathetic nervous system on nocturnal bronchial obstruction. Clin Sci (Lond) (1985) 1.64
Major genes regulating total serum immunoglobulin E levels in families with asthma. Am J Hum Genet (2000) 1.63